There have recently been a number of newspaper that leaped feverishly upon the results of the SELECT research trial that concluded that men supplementing with 400IU of vitamin E had an increased risk of developing cancer. I would like to take a moment to examine this issue both in and with more depth.
Firstly, I think it bears reiterating first and foremost that vitamin E is an essential human nutrients and that attempts to avoid vitamin E intake entirely in an attempt lower prostate cancer risk would be misguided and cause serious health consequences, including potentially fatal disease. Furthermore, Vitamin E deficiency is the most prevalent nutrient deficiency in North America,with an estimate of over 90% of adults not meeting the daily requirements according to a 2004 study published in the Journal of the American Dietetic Association (1).
The role of Vitamin E and prostate cancer prevention seems to be controversial and there is presently no scientific consensus. The following information is provided by the Linus Pauling Institute at Oregon State University.
A recently published meta-analysis of 12 randomized controlled trials concluded that vitamin E supplementation was not associated with overall cancer incidence, cancer mortality, or total mortality(2). However, vitamin E supplementation may possibly reduce the risk of prostate cancer. A placebo-controlled intervention study that was designed to look at the effect of alpha-tocopherol supplementation on lung cancer development noted a 34% reduction in the incidence of prostate cancer in smokers given daily supplements of 50 mg of synthetic alpha-tocopherol (equivalent to 25 mg of RRR-alpha-tocopherol) daily(3). A meta-analysis that combined the results of this study with three other randomized controlled trials associated vitamin E supplement use with a 15% lower risk of prostate cancer (2). However, a large randomized,placebo-controlled intervention study using alpha-tocopherol and selenium supplementation (trial name: SELECT), alone or in combination, was recently halted because there was no evidence of benefit in preventing prostate cancer (4, 5). After an average of 5.5 years of follow-up in SELECT, participants taking vitamin E (400 IU/day of all-rac-alpha-tocopherol) alone had a higher risk of prostate cancer, but the increase was not statistically significant (6). A subsequent analysis (median follow-up of 7 years) after the trial was halted found that men who
took the vitamin E supplement had a statistically significant, 17% higher risk of prostate cancer compared to men who took a placebo (7).
Please note that the result of the SELECT study showing a 17% increase in prostate cancer risk are an anomaly and the reasons for these results, including potential problems with the methodology and data interpretation, are currently being debated. The form of vitamin E used in this trial was also synthetic, and there seems to be a greater tendency for synthetic vitamin E to produce negative results in trials.
Furthermore, the results of The Selenium and Vitamin E Cancer Prevention Trial (SELECT), also showed that group receiving either selenium or selenium plus vitamin significantly reduced their risk of prostate cancer, though this is largely ignored by the research in their conclusions on the trial, and in the media reporting.
If one were to err entirely on the side of caution, it is worth noting that many of the studies showing negative or conflicting results are with higher dosage vitamin
E (>400IU per day) of synthetic alpha-tocopherol only. There are no negative reports using mixed tocopherols that we are aware of, nor do there seem to be negative reports involving supplementation of equal to or less than 200IU per day.
Furthermore, there is ample, compelling positive research behind vitamin E supplementation for other health conditions.
Vitamin E has an effectiveness rating according to the Natural Medicines Comprehensive Database for the following conditions (Please note this list in not comprehensive: research citations are available though the website at http://naturaldatabase.therapeuticresearch.com):
Age-related macular degeneration (AMD). Taking vitamin E 400 IU orally, plus elemental zinc 80 mg, vitamin C 500 mg, and beta-carotene 15 mg daily seems to provide a risk reduction of 27% for visual acuity loss and a risk reduction of 25% for progression of AMD in patients with advanced AMD. Some research suggests that increasing dietary intake of vitamin E, either alone or along with increasing dietary vitamin C, beta-carotene, and zinc, seems to decrease the risk of developing AMD.
Alzheimer's disease. There's some evidence that all-rac-alpha-tocopherol (synthetic vitamin E) 2000 IU per day is similar to selegiline (Eldepryl), and superior to placebo, for slowing cognitive function decline in patients with moderately severe Alzheimer's disease. But there doesn't appear to be an additive effect when vitamin E is used in combination with selegiline (Eldepryl).
Retrospective data suggest that long-term combination therapy with donepezil (Aricept) 5 mg and vitamin E 1000 IU per day may help slow cognitive decline in patients with Alzheimer's disease.
Anemia. Two small studies in adults and children on chronic hemodialysis have shown improved response to erythropoietin with vitamin E supplementation. In one study, children given vitamin E 15 mg/kg in combination with erythropoietin had significantly increased hemoglobin (Hgb) and hematocrit (Hct) levels after 2 weeks of combination treatment compared to eight and five weeks in patients without combination treatment. In the other study of adults, concurrent supplementation with vitamin E 500 mg daily allowed dose reductions of erythropoietin from an
average of 93 U/kg/week to 74 U/kg/week with the same results on Hgb levels.
Bladder cancer. Taking vitamin E 200 IU orally for greater than 10 years seems to be associated with a reduced risk of bladder cancer mortality.
Cisplatin-induced neurotoxicity. Alpha-tocopherol administered before chemotherapy, and continued for 3 months after the completion of treatment, seems to reduce the incidence of peripheral neurotoxicity by 55% without affecting cisplatin efficacy.
Common-cold: A randomized, placebo-controlled trial in elderly nursing home residents reported that daily supplementation with 200 IU of synthetic alpha-tocopherol (equivalent to 90 mg of RRR-alpha-tocopherol) for one year significantly lowered the risk of contracting upper respiratory tract infections, especially the common cold, but had no effect on lower respiratory tract (lung) infections.
Dementia. A longitudinal cohort study of 3,385 elderly men aged 71 to 93 years found that men who consumed supplemental vitamin E and vitamin C had a decreased risk of developing vascular and mixed or other dementias; however, there was no protective effect for Alzheimer's dementia. This study did not distinguish between different forms of vitamin E.
Dysmenorrhea. Taking vitamin E 200 IU twice daily or 500 IU daily starting 2 days before menstruation and continuing through the first 3 days of bleeding seems to reduce menstrual pain severity and duration and decrease blood loss in teenage girls with primary dysmenorrheal.
Huntington's disease. RRR-alpha-tocopherol (natural vitamin E) can significantly improve symptoms in patients with early Huntington's disease, but this benefit is not seen in patients with more advanced disease.
Infertility. In one study, males with asthenospermia or oligoasthenospermia, receiving oral vitamin E supplementation, achieved impregnation at a rate of 21% compared to none for similar patients receiving placebo. In another study, males enrolled in an in vitro fertilization program who had previously had low fertilization rates were treated with oral vitamin E for three months. Fertilization rates increased significantly from 19% to 29% after one month of treatment. In a crossover trial, males found to have elevated reactive oxygen species in their semen, which might be associated with infertility, were treated with oral vitamin E. After treatment, in vitro sperm binding to the zona pellucida was significantly increased. Interestingly, high-dose vitamin
E in combination with vitamin C does not seem to offer any benefit to sperm functionality. Vitamin E plus selenium seems to improve sperm functionality. Studies did not differentiate between different forms of vitamin E.
Ischemic stroke. Some clinical research shows that taking all-rac-alpha-tocopherol (synthetic vitamin E) might reduce the risk of ischemic stroke in male smokers with hypertension and diabetes. A meta-analysis of studies shows that vitamin E in doses of 300-800 IU daily,
including both natural and synthetic forms, does not significantly affect total stroke risk.
However, it significantly reduces the risk of ischemic stroke by 10%. This means that one ischemic stroke will be prevented for every 476 patients taking vitamin E. In contrast to this finding, the analysis also found that vitamin E increases the risk of hemorrhagic stroke by 22%. This means that there will be one additional hemorrhagic stroke for every 1250 patients taking vitamin E.
Nonalcoholic steatohepatitis (NASH). In adults with NASH, taking vitamin E 800 IU daily for 24 months significantly improves liver enzymes, hepatic steatosis, and lobular inflammation. Other research also shows that taking vitamin E in combination with vitamin C might improve hepatic fibrosis in patients with NASH. However, it does not seem to affect inflammation. Taking vitamin E 400-1200 IU in children with NASH also seems to improve liver enzyme levels after 4-10 months of treatment.
Parkinson's disease. Preliminary evidence suggests that dietary vitamin E intake might be associated with a decreased occurrence of Parkinson's disease. But taking all-rac-alpha- tocopherol (synthetic vitamin E) 2000 IU supplements daily does not seem to have any benefit for patients who have Parkinson's disease.
Pre-eclampsia. Taking a combination of vitamin E 400 IU and vitamin C 1000 mg daily significantly reduced the risk of proteinuric hypertension in high-risk women when started in weeks 16 to 22 of pregnancy. Other researchers using vitamin E in combination with vitamin C and allopurinol beginning at 24 to 32 weeks gestation found the combination similar to placebo.
Premenstrual syndrome (PMS). Taking vitamin E orally seems to reduce symptoms of anxiety, craving, and depression in patients with PMS.
Physical performance. Population research suggests that increasing intake of dietary vitamin E is associated with increased physical performance and muscle strength in elderly people.
Rheumatoid arthritis (RA). Vitamin E taken orally in conjunction with standard therapy is superior to standard therapy alone for reducing pain in patients with RA.
While it may seem that the last thing the press wants is a multifaceted debate, the majority of the evidence does not support the damnation that vitamin E supplements have received in the press, and it would be far more beneficial to their readers to bear this out more in the reporting of health news.
There are doubtless people are more at risk of the adverse effects of supplementing any substance, but knowledgeable healthcare professionals who are intimately familiar with their patients are the best people for assessing these risks, not the media.
And fear mongering has no place in patient care.
References:
1. Maras JE, Bermudez OI, Qiao N, Bakun PJ, Boody-Alter EL, Tucker KL. Intake of
alpha-tocopherol is limited among US adults. J Am Diet Assoc. 2004;104(4):567-575.
2. Alkhenizan A, Hafez K. The role of vitamin E in the prevention of cancer: a meta-
analysis of randomized controlled trials. Ann Saudi Med. 2007;27(6):409-414. (PubMed)
3. Heinonen OP, Albanes D, Virtamo J, et al. Prostate cancer and supplementation with
alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl
Cancer Inst. 1998;90(6):440-446. (PubMed)
4. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the next prostate
cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol.
2001;166(4):1311-1315. (PubMed)
5. National Cancer Institute. Review of Prostate Cancer Prevention Study Shows No Benefit
for Use of Selenium and Vitamin E Supplements. [Web page]. Available at: http://
www.cancer.gov/newscenter/pressreleases/SELECTresults2008. Accessed 10/28/08.
6. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of
prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial
(SELECT). JAMA. 2009;301(1):39-51. (PubMed)
7. Klein EA, Thompson IM, Jr., Tangen CM, et al. Vitamin E and the risk of prostate
cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA.
306(14):1549-1556. (PubMed)


